⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
AZN News
AstraZeneca PLC
Form 8-K
sec.gov
MKC-V
MKC
AZN
ZM
Sonar Named a Leader in the 2026 Gartner® Magic Quadrant™ for Technical Debt Management Tools
prnewswire.com
NVDA
NOW
BKNG
GS
AZN
F
Artios Announces First Patient Dosed in Randomized Phase 2 POLKA Study Evaluating DNA Polymerase Theta Inhibitor ART6043 in gBRCA-mutated HER2-Negative Breast Cancer
globenewswire.com
AZN
Emerging Hope in Multiple Myeloma Market: 7 Late-Stage Therapies Nearing the Finish Line | DelveInsight
globenewswire.com
AZN
ABBV
GILD
BMY
DATROWAY ® (datopotamab deruxtecan-dlnk) approved in the US as first TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic triple-negative breast cancer who are not PD-1/PD-L1 inhibitor candidates
businesswire.com
AZN
Datroway ® Approved in the U.S. as First TROP2 Directed Antibody Drug Conjugate for First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates
businesswire.com
AZN
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors
businesswire.com
AZN
AstraZeneca to showcase Phase III data in liver, breast and bladder cancers and potential first-in-class rare disease therapy at ASCO 2026
businesswire.com
AZN
Cutaneous T-Cell Lymphoma Clinical Trial Pipeline Accelerates as 30+ Pharma Companies Rigorously Developing Drugs for Market Entry | DelveInsight
globenewswire.com
SNGX
IPHA
BMY
NKTX
AZN
MRK
TAK
NVS
GMAB
ABBV
BIIB
CRSP
INCY
ALKS
PFE
REGN
GILD
AMGN
Pemphigus Vulgaris Market Analysis Report 2026-2036, Profiles of F. Hoffmann La Roche, Argenx, Sanofi, Syntimmune, Allmiral, Cabaletta Bio, and Novartis
globenewswire.com
MRK
SNY
AZN
REGN
JNJ
CABA